Insights

THOUGHT LEADERSHIP PIECES FROM COPENHAGEN ECONOMICS

These Insight Pieces showcase our expertise and unique perspectives on trending and emerging issues. These insights provide valuable analysis on a wide range of topics, with the aim of keeping you informed.

Healthcare & Life Sciences

Real-world evidence on the economic implications of CGRP
Competition

GENERATIVE AI PARTNERSHIPS: SEPARATING GOOD FROM BAD
Healthcare & Life Sciences

Enabling, not rewarding: How to design a high unmet medical
Healthcare & Life Sciences

Cost and value of regulatory data protection
TMT & Digital

Cloud on the regulatory horizon? A time of reckoning for

Our latest blog posts

The price-cost test in the Art 102 new draft guidelines: when and how to use it

August 8, 2024 The European Commission has published the long-awaited new draft Guidelines on the application of Article 102. The document...

GENERATIVE AI PARTNERSHIPS: SEPARATING GOOD FROM BAD

August 1, 2024 Generative AI promises to reshape the digital world. Agreement is widespread that this technology will have a significant...

The Road Becomes Clearer

July 30, 2024 The Commission provides initial clarifications on distortion and balancing tests. In a recent staff working paper, the Commission...

Regulatory data protection for pharmaceuticals – How implementing RDP in China will benefit society, industry and the Chinese economy

July 17, 2024 China’s ambition of a successful innovative pharmaceutical industry needs more fuel China has an ambition to strengthen its...

Cloud on the regulatory horizon? A time of reckoning for the EU telecoms industry

June 24, 2024 Cloud is subject to regulatory scrutiny​ To achieve the EU’s “Digital Decade” targets, significant investments in cloud infrastructure...

Cost and value of regulatory data protection

May 27, 2024 The European Union (EU) General Pharmaceutical Legislation (GPL) lays down provisions related to medicinal products authorisation and post-authorisation...

Enabling, not rewarding: How to design a high unmet medical needs category to drive, not deter, innovation in orphan medicinal products

May 15, 2024 In light of the European Commission’s recent proposal to revamp the incentive system for orphan medicinal product (OMP)...

Reduced regulation for telecoms? A time of reckoning for the EU telecoms industry

May 6, 2024 EU Telecoms regulation soon to get a revamp The EU may soon see a significant shift in telecoms...

Real-world evidence on the economic implications of CGRP inhibitors as preventive treatment of migraine in Denmark

April 4, 2024 Migraine is a serious condition with large implications for patients. Some patients with severe migraine can receive preventive...

Quality: A game changer in market definition?

March 14, 2024 A key change in the recently published Market Definition Notice is the greater emphasis on non-price elements as...